Total Debt to Capital: NuCana Corp (NCNA)

NuCana plc (NCNA) possesses high growth potential through its patent holdings, which enable the scaling of global drug distribution with low costs. Current price action regarding the total debt-to-equity ratio stands at 0.03. Future revenues are based on the commercialization of ProTide drugs targeting solid tumors. As the company currently has no marketed products, its valuation relies exclusively on clinical trial results.

This ratio measures the degree of financial leverage by comparing total liabilities to equity to assess the business's dependence on borrowed capital and default risks. In the context of NuCana plc (NCNA), the total debt-to-equity ratio reflects the cost of financing the development of oncology drugs, allowing investors to evaluate balance sheet stability during expensive late-stage clinical trials.